Related Experiment Video
Updated: Aug 5, 2025

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
Published on: December 23, 2022
Automated high-throughput image processing as part of the screening platform for personalized oncology
Marcel P Schilling1, Razan El Khaled El Faraj2, Joaquín Eduardo Urrutia Gómez2
1Institute for Automation and Applied Informatics, Karlsruhe Institute of Technology, 76344, Eggenstein-Leopoldshafen, Germany. marcel.schilling@kit.edu.
Abstract:
Cancer is a devastating disease and the second leading cause of death worldwide. However, the development of resistance to current therapies is making cancer treatment more difficult. Combining the multi-omics data of individual tumors with information on their in-vitro Drug Sensitivity and Resistance Test (DSRT) can help to determine the appropriate therapy for each patient. Miniaturized high-throughput technologies, such as the droplet microarray, enable personalized oncology. We are developing a platform that incorporates DSRT profiling workflows from minute amounts of cellular material and reagents. Experimental results often rely on image-based readout techniques, where images are often constructed in grid-like structures with heterogeneous image processing targets. However, manual image analysis is time-consuming, not reproducible, and impossible for high-throughput experiments due to the amount of data generated. Therefore, automated image processing solutions are an essential component of a screening platform for personalized oncology. We present our comprehensive concept that considers assisted image annotation, algorithms for image processing of grid-like high-throughput experiments, and enhanced learning processes. In addition, the concept includes the deployment of processing pipelines. Details of the computation and implementation are presented. In particular, we outline solutions for linking automated image processing for personalized oncology with high-performance computing. Finally, we demonstrate the advantages of our proposal, using image data from heterogeneous practical experiments and challenges.
Insights
Automated image analysis of drug sensitivity and resistance tests (DSRT) advances personalized oncology. This platform integrates multi-omics data and DSRT for tailored cancer therapies, overcoming manual analysis limitations.
Area of Science:
- Oncology
- Bioinformatics
- Medical Imaging
Background:
- Cancer is a leading cause of death globally, with treatment hindered by therapy resistance.
- Personalized oncology requires integrating multi-omics data with in-vitro Drug Sensitivity and Resistance Tests (DSRT).
- High-throughput screening platforms are crucial for personalized cancer care.
Purpose of the Study:
- To develop an automated image processing platform for high-throughput DSRT in personalized oncology.
- To address the limitations of manual image analysis in processing large datasets from DSRT experiments.
- To integrate multi-omics data with DSRT profiling for improved cancer therapy selection.
Main Methods:
- Development of a platform incorporating DSRT profiling workflows using minute cellular material.
- Implementation of assisted image annotation and algorithms for processing grid-like high-throughput experimental images.
- Integration of automated image processing with high-performance computing and deployment of processing pipelines.
Main Results:
- Demonstration of a comprehensive concept for automated image processing in personalized oncology.
- Successful linking of automated image analysis for DSRT with high-performance computing resources.
- Validation of the proposed solution using image data from heterogeneous practical experiments.
Conclusions:
- Automated image processing is essential for enabling high-throughput screening platforms in personalized oncology.
- The developed platform facilitates efficient and reproducible analysis of DSRT data.
- This approach enhances the potential for determining optimal cancer therapies based on individual patient data.

